Baird Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $132
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $67 to $132.
Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $67 to $132.